

Figure 1 is a representation of the pmCD79b-r4 (mouse (m) Ig β -human (h) IgG.Fc) fusion protein construct.

REMARKS


In response to the Notice to File Missing Parts of Non-Provisional Application mailed from the Patent Office on July 16, 2001, Applicants hereby submit a sequence listing containing pages 1-2 to be included in the specification part of the disclosure. The sequence listing contains sequences which were in the specification as filed.

Support for the amendment to page 7 can be found in Figure 1 as filed. No new matter has been added to the application. A version showing changes made is attached as Appendix A.

CONCLUSION

Applicants respectfully submit that the above-identified application is now in condition for allowance. If a telephone conversation with Applicants' Attorney would expedite prosecution of the above-identified application, the Examiner is urged to call Applicants' Attorney at (617) 227-7400.

Respectfully submitted,



Megan E. Williams, Esq.

Reg. No.: 43,270

Attorney for Applicant

LAHIVE & COCKFIELD, LLP
28 State Street
Boston, MA 02109
Tel. (617) 227-7400

Dated: November 15, 2001

APPENDIX A

VERSION SHOWING CHANGES MADE

At page 7, lines 9 and 10 have been changed as follows:

Figure 1 is a representation of [a] the pmCD79b-r4 (mouse (m) [CD79b (] Ig β [])-human (h) IgG.Fc) [γ 4] fusion protein construct.